Skip to main content

ADVERTISEMENT

Scott Byrd

IAGS (International Andreas Gruentzig Society) Proceedings
08/01/2008
Philip Reid (Eli Lilly & Company): Speaking as a cardiologist, not as a neurologist, I find that the challenge with the trial that Renato has just described is to demonstrate the efficacy of abciximab in acute nonhemorrhagic stroke patients....
Philip Reid (Eli Lilly & Company): Speaking as a cardiologist, not as a neurologist, I find that the challenge with the trial that Renato has just described is to demonstrate the efficacy of abciximab in acute nonhemorrhagic stroke patients....
Philip Reid (Eli Lilly &...
08/01/2008
Journal of Invasive Cardiology